Shanghai Fosun Pharmaceutical(02196): The drug registration application for cyclophosphamide injection has been accepted.

Shanghai Fosun Pharmaceutical (02196) announced that its holding subsidiary, Gismei (Wuhan) Pharmaceutical Co., Ltd., recently had its drug registration application for cyclophosphamide injection accepted by the National Medical Products Administration. The drug is a chemical drug independently developed by the group and is intended for the treatment of adult and pediatric patients with the following diseases: malignant lymphoma, Hodgkin's disease, lymphoblastic lymphoma, mixed cell lymphoma, T-cell lymphoma, Burkitt lymphoma, multiple myeloma, leukemia, fungal granulomas, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast cancer. As of December 2025, the group's cumulative research and development investment for this drug is approximately RMB 7.4 million (unaudited).